SWOG clinical trial number
CTSU/R1306
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Closed
Phase
Abbreviated Title
Rand Ph II, Individualized Combined Modality, Stage III NSCLC
Status Notes
This study closed to accrual on 12/20/17.
Activated
09/01/2013
Closed
12/20/2017
Participants
CTSU
Research committees
Lung Cancer
Treatment
Radiation Therapy
Erlotinib
Crizotinib
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA5231
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
SWOG Clinical Trial Number
S2414
INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A082304/S2402
Perioperative Versus Adjuvant Systemic Therapy In Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG, CTIU2317
Research Committee(s)
Lung Cancer
Activated
12/11/2024
Open